INHALED BECLOMETHASONE TO PREVENT CHRONIC LUNG DISEASE

本研究旨在阐明新生儿慢性肺部疾病发生的机制，并测试吸入糖皮质激素预防慢性肺部疾病及其对生长发育的伴随影响的能力和安全性。 这将通过一项随机、安慰剂对照的吸入性皮质类固醇二丙酸倍氯米松临床试验在出生体重小于1251 gm且妊娠小于33周的婴儿中完成，这些婴儿在3 - 14天龄时继续需要机械通气。 将使用带雾化器装置的定量吸入器，使用麻醉袋通过手动通气给予倍氯米松，治疗期为28天。

This study has been designed to elucidate mechanisms by which neonatal chronic lung disease occurs and to test the capacity and safety of inhaled glucocorticoid to prevent the process of chronic lung disease and its accompanying effects on growth and development. This will be accomplished through a randomized, placebo controlled clinical trial of inhaled corticosteroid, beclomethasone dipropionate, in infants less than 1251 gm birth weight and less than 33 weeks gestation who, at 3 to 14 days of age, continue to require mechanical ventilation. Beclomethasone will be administered via manual ventilation with an anesthesia bag using a metered dose inhaler with a spacer device for a 28-day treatment period.